Patients with connective tissue disease-related interstitial lung disease show slower decline in lung function and longer ...

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks.

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and ...

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis PR Newswire BOSTON, June 5, 2025 First-in-class agent targets WISP1 in patients with IPF ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The trials were conducted with idiopathic pulmonary fibrosis patients or IPF (FIBRONEER-IPF study), and in secondary progressive pulmonary fibrosis (FIBRONEER-ILD study).

• Periostin (POSTN) is a valuable idiopathic pulmonary fibrosis (IPF) serum biomarker with better diagnostic performance than Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and ...

Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmonary fibrosis is needed.

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 ...